Study identifier:KU36-73
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours
Melanoma neoplasms
Phase 1
No
KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
All
40
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
KuDOS Pharmaceuticals Ltd (a member of the AstraZeneca Group of companies)
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic chemotherapy.
Location
Location
Oxford, United Kingdom
Location
Pittsburgh, PA, United States
Location
Manchester, United Kingdom
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 DTIC + KU-0059436 | Drug: KU-0059436 (AZD2281)(PARP inhibitor) oral Other Name: Olaparib Drug: dacarbazine intravenous injection over at least 20 minutes Other Name: DTIC |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.